2024
Immunotherapy Initiation at the End of Life in Patients With Metastatic Cancer in the US
Kerekes D, Frey A, Prsic E, Tran T, Clune J, Sznol M, Kluger H, Forman H, Becher R, Olino K, Khan S. Immunotherapy Initiation at the End of Life in Patients With Metastatic Cancer in the US. JAMA Oncology 2024, 10: 342-351. PMID: 38175659, PMCID: PMC10767643, DOI: 10.1001/jamaoncol.2023.6025.Peer-Reviewed Original ResearchNon-small cell lung cancerEnd of lifeMonth of deathImmunotherapy initiationCohort studyMAIN OUTCOMEStage IV non-small cell lung cancerCharlson-Deyo comorbidity indexHigh metastatic burdenInitiation of immunotherapyNational prescribing patternsRisk-adjusted patientsImmune checkpoint inhibitorsRetrospective cohort studyStage IV melanomaPercentage of patientsHigh-volume centersLocation of metastasesLow-volume centersOdds of deathCell lung cancerNational Clinical DatabaseLow-volume facilitiesDrug Administration approvalCheckpoint inhibitors
2023
Outcomes on an inpatient oncology service after the introduction of hospitalist comanagement
Morris J, Rothberg BE, Prsic E, Parker N, Weber U, Gombos E, Kottarathara M, Billingsley K, Adelson K. Outcomes on an inpatient oncology service after the introduction of hospitalist comanagement. Journal Of Hospital Medicine 2023, 18: 391-397. PMID: 36891947, DOI: 10.1002/jhm.13071.Peer-Reviewed Original ResearchConceptsLength of stayInpatient oncology serviceSmilow Cancer HospitalSeverity of illnessOncology servicesOncologists' experiencesReadmission ratesEarly dischargeHospitalist comanagementAverage LOSTime of dischargeMean discharge timeEarly discharge ratesImpact of hospitalistsRace/ethnicityDischarge dispositionMultiple admissionsCancer HospitalMAIN OUTCOMEStudy durationPatient volumeCancer typesStudy periodHospitalistsOutcomes